Overview

* Corcept Q3 2025 revenue of $207.6 mln, missed analyst expectations

* Net income for Q3 2025 decreased to $19.7 mln from $47.2 mln last year

* Company expands oncology programs with new cancer studies

Outlook

* Corcept modifies 2025 revenue guidance to $800 mln - $850 mln

* Company expects to meet increasing demand with new specialty pharmacies

* Corcept anticipates important clinical trial results by early next year

Result Drivers

* HYPERCORTISOLISM DEMAND - Surge in demand for Korlym driven by growing recognition of hypercortisolism's prevalence, per CEO Joseph K. Belanoff

* CAPACITY CONSTRAINTS - Revenue impacted by capacity constraints at previous specialty pharmacy vendor, new pharmacies added to meet demand, per CEO Joseph K. Belanoff

* ONCOLOGY EXPANSION - Expanded oncology programs with new studies in various cancers, including ovarian and pancreatic, in combination with chemotherapy and immunotherapy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $207.63 $218.52

Revenue mln mln (4

Analysts

)

Q3 EPS $0.16

Q3 Net $19.7

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Corcept Therapeutics Inc ( CORT ) is $137.50, about 46.1% above its November 3 closing price of $74.17

* The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)